文献速递肝病消化道肿瘤与早癌

直接抗病毒治疗与失代偿期肝硬化患者肝细胞癌的关联

The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-05-31

基于国家登记研究,比较DAA治疗后发生肝细胞癌(HCC)的80例患者与165例未发生HCC者。基线非恶性肝脏病变(HR 1.99)、血小板减少(HR 1.59)和糖尿病(HR 1.68)与HCC风险升高相关;HCC组持续病毒学应答(SVR)率低于无HCC组(68% vs 87%,P<0.001,OR 3.13)。病毒血症与否对肿瘤大小、进展或生存无差异。

要点

  • 基线非恶性肝脏病变、血小板减少和糖尿病与DAA治疗后HCC风险升高相关。
  • 发生HCC者SVR率低于未发生HCC者(68% vs 87%)。
  • 病毒血症状态对HCC后肿瘤大小、进展或生存无差异。

核心结论

  • HCV治疗后发生HCC不改变预后或肿瘤进展,但基线非恶性肝脏病变、糖尿病和血小板减少增加HCC风险,且HCC与SVR率降低相关。

研究设计与样本

  • 基于国家晚期肝病登记研究,80例DAA治疗后发生HCC的患者按频率匹配165例未发生HCC者,治疗时间2014年6月至2015年9月,采用多变量分析和Kaplan-Meier估计。

主要发现

  • 基线非恶性肝脏病变(HR 1.99)、血小板减少(HR 1.59)和糖尿病(HR 1.68)增加HCC可能性。
  • HCC组SVR 54/80(68%) vs 无HCC组143/165(87%),P<0.001,OR 3.13(95%CI 1.64-5.99)。
  • 病毒血症与非病毒血症患者之间肿瘤大小、进展或生存无差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct-acting anti-viral therapy (DAA) has transformed hepatitis C virus (HCV) care, particularly in patients with decompensated cirrhosis. However, their impact on hepatocellular carcinoma (HCC) remains unclear. AIM: To use a national registry of patients with advanced liver disease to explore the relationship between DAA therapy and HCC. METHODS: All patients with de novo HCC post DAA therapy were frequency matched with patients who did not develop HCC. Demographic, clinical and laboratory data were obtained. Cross-sectional imaging and multidisciplinary team reports were reviewed for dates of HCC diagnosis and HCC progression. Patients were categorised by treatment outcome and time of HCC development. Data were examined by multivariable analysis and Kaplan-Meier estimation. RESULTS: Eighty patients with HCC were compared with 165 patients without HCC, treated between June 2014 and September 2015. Mean follow-up from start of DAA therapy was 32.4 months. Twenty-eight patients were diagnosed with early HCC (within 6 months of therapy) and 52 presented late. Baseline nonmalignant lesions (HR: 1.99), thrombocytopaenia (HR: 1.59) and diabetes (HR: 1.68) increased likelihood of HCC. Response to therapy was reduced in patients who developed liver cancer (SVR in patients with HCC = 54/80 (68%), SVR in patients without HCC = 143/165 (87%), P < 0.001, OR: 3.13, 95% CI: 1.64-5.99). We found no difference between tumour size, progression or survival between viraemic and nonviraemic patients. CONCLUSION: There is no alteration in prognosis or cancer progression following HCC development after HCV treatment. However, baseline nonmalignant liver lesions, diabetes and thrombocytopaenia increase the risk of HCC, and HCC is associated with a decreased SVR rate.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mecci AJ, Kemos P, Leen C, et al. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 31149748. doi:10.1111/apt.15296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。